Welcome to the Iovance Biotherapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. My name is Gigi, and I will be your operator for today’s call. Please note that this conference is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, you may begin.

Thank you, operator. Good afternoon and thank you for joining us. Speaking on today’s call, we have Dr. Fred Vogt, our Interim President and Chief Executive Officer; Dr. Igor Bilinsky, our Chief Operating Officer; Jim Ziegler, our Executive Vice President, Commercial; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer. Dr. Raj Puri, our Executive Vice President, Regulatory Strategy and Translational Medicine, is also available for the Q&A session. This afternoon, we issued a press release that can be found on our corporate website at iovance.com, which includes the financial results for the three and twelve months ended on December 31, as well as recent corporate updates. Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance’s goals, business focus, business plans and transactions, pre-commercial activities, clinical trials and results, regulatory interactions, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interactions, licenses and collaborations, cash position and expense guidance, and future updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected during today’s call. We undertake no obligation to publicly update any forward-looking statements. With that, I will turn the call over to Fred.

Thank you, Sara, and good afternoon, everyone. I am pleased to highlight the positive milestones and significant progress at Iovance in 2022 and into the beginning of 2023. We are close to completing our biologics license application, or BLA, for our lead TIL therapy, lifileucel, in advanced melanoma before the end of this quarter. We are also preparing for commercialization, developing a robust immuno-oncology pipeline integrating Proleukin upon the close of our planned acquisition. The BLA for lifileucel remains our number one priority on behalf of patients with advanced melanoma who progress on or after anti-PD-1 therapy. This represents a significant unmet medical need given that there are currently no FDA approved treatment options in this setting. We feel very confident going into the BLA review process given the strength of our clinical data and unmet need, as well as several positive interactions with and feedback from the FDA during 2022. These included FDA alignment on the potency assay matrix last April and a successful pre-BLA meeting in July, where the FDA provided favorable feedback on the clinical efficacy data from Cohorts 2 and 4 of our C-144-01 clinical trial, including duration of follow-up and that the clinical and safety dataset was sufficient for a BLA review. In the fourth quarter, we also reached agreement with the FDA on our recently started TILVANCE-301 Phase 3 trial, frontline advanced melanoma to serve as a registrational trial indication as well as a confirmatory study supporting full approval of lifileucel in post anti-PD-1 advanced melanoma. We expect TILVANCE-301 to be well underway at the time of potential approval, and Frederick will talk about additional details to the trial on today’s call. Overall, the FDA continues to be engaged and supportive. We look forward to continuing this level of collaboration in 2023. We are also preparing to integrate Proleukin upon the close of our planned acquisition of this product. As a reminder, we announced last month that we have entered into a strategic transaction with Clinigen to acquire worldwide rights to Proleukin, an IL-2 product with currently approved indications. It is importantly also used to promote T-cell activity following TIL infusions. We have a strong strategic fit and rationale for this transaction, which provides immediate and future revenue and full control of the IL-2 supply chain and logistics surrounding TIL therapy and is expected to lower clinical trial expenses and future cost of goods for lifileucel. In addition to lifileucel in melanoma, we are building a deep and diverse TIL therapy pipeline in multiple solid tumor types that has the potential to create significant value for cancer patients as well as our shareholders. We are conducting six active clinical trials preparing to randomize patients in the frontline melanoma treatment setting and our first Phase 3 study in advancing several genetically modified TIL therapies, which Frederick will also highlight on today’s call. As we grow our organization to prepare for our first potential launch, we currently have more than 500 Iovance employees who have expertise in developing and commercializing oncology and cell and gene therapy products. I look forward to addressing your questions later during this call. And we will now ask Igor to address our manufacturing updates and preparations to supply commercial TIL therapies upon potential approval.

Thank you, Fred. Manufacturing is critical for any commercial launch, particularly for autologous TIL therapies. So our top priority is to prepare for commercial supplies to meet patient needs, while continuing to scale up our internal capabilities and staffing. We are focused on operational excellence and maintaining a consistent TIL manufacturing success rate of more than 90% in more than 600 patients treated with Iovance TIL therapy to date. We are currently supplying clinical studies from iCTC, which is operating flex suites for clinical manufacturing and core suites for BLA readiness activities in preparation for commercial manufacturing. We have done significant work to ensure that iCTC and our contract manufacturers’ facility are well prepared for launch, with many of our current efforts focused on the FDA pre-approval inspections that we expect to occur during the BLA review process. The iCTC is expected to supply most of the commercial TIL therapies upon approval, with contract manufacturers to provide additional flexibility to optimally balance capacity and patient demand. Beyond our initial launch of lifileucel, we are planning for future capacity needs as we look to establish TIL as the next paradigm-shifting class of cancer therapy. The iCTC is currently built with an annual capacity to supply TIL products for more than 2,000 patients with available shelf space that we can build out to supply products for more than 5,000 patients annually from this facility. Longer term, by adding new facilities as well as streamlining and automating manufacturing processes, our vision is to build capacity for more than 10,000 patients annually. Our intellectual property, or IP, is also a critical component to support and protect our proprietary manufacturing processes and know-how and to further solidify our global leadership in TIL therapy. We currently own at least 60 granted or allowed U.S. and international patents, including Gen 2 patent rights that are expected to provide exclusivity into 2038. Extensive detail on Iovance-owned IP is highlighted on our corporate website and within our annual report on Form 10-K. I would now like to hand the call to Jim Ziegler to highlight our commercial launch preparations.

Thank you, Igor. Throughout 2022, the commercial team made steady progress toward launch. With the ongoing BLA submission, our launch priorities include onboarding of our authorized treatment centers, or ATCs, securing appropriate access, and achieving operational readiness. Our cross-functional teams continue to partner with and onboard ATCs to develop new workflows that are unique to TIL therapy while leveraging workflows within existing cell therapy service lines at these centers. Our ATC operations and regional account director teams have structured interactions to support an efficient ATC onboarding process, and we have developed a training curriculum to ensure multidisciplinary teams can administer the lifileucel treatment regimen upon FDA approval. The timing and execution of key onboarding activities and training at each center are aligned to our regulatory timelines. We support each center in developing their TIL service line and we plan just-in-time training to ensure launch readiness. Our reimbursement strategies are focused on securing coding, coverage, and payment. Our market access team continues to engage key national and regional payers. As we transition from the clinical trial to commercially approved setting, our goal is to ensure patients have appropriate and timely access to lifileucel. Our cross-functional team is also assessing our needs and capabilities and developing our implementation plan for Proleukin. We are also fortunate to have several cross-functional team members with prior Proleukin leadership experience who are leading and developing our end-to-end integration processes. We are preparing for a smooth transfer and operational readiness for Proleukin upon the close of our planned acquisition. We understand that launching an autologous cell therapy requires sustained operational excellence, and I want to acknowledge the critical thinking, problem-solving and tireless efforts of our cross-functional team. Our team has set a high bar for themselves to ensure the highest quality of operational excellence. We are well positioned to scale our efforts to ensure commercial launch readiness. I will now pass the call to Friedrich Finckenstein, our Chief Medical Officer, to highlight our clinical progress.

Thank you, Jim. Today, I would like to summarize our TIL therapy pipeline and next-generation technology. I will begin with our multi-pronged strategy in advanced melanoma. Our ongoing rolling DNA submission for lifileucel in post anti-PD-1 advanced melanoma is based on the results from our C-144-01 trial, the largest single clinical study ever conducted for TIL therapy in post-ICI melanoma. In the fourth quarter, we presented positive data from C-144-01 Cohorts 2 and 4 to the medical community for the first time at the Society for Immunotherapy of Cancer for SITC Annual Meeting last November and published results from the study in the Journal of Immunotherapy of Cancer or JITC in December. We are confident that the strength of the clinical data from 153 patients and the C-144-01 trial, including our pivotal Cohort 4 in support of Cohort 2, supports approval. Following the recent posting of our Phase 3 TILVANCE-301 trial in frontline advanced melanoma on clinicaltrials.gov, I would like to highlight additional detail on this trial to-date. We reached agreement with the FDA for TILVANCE-301 to serve as our registrational trial for full approval of lifileucel in combination with pembrolizumab in frontline advanced melanoma as well as a confirmatory trial to support full approval of lifileucel in post-anti-PD-1 advanced melanoma. Notably, we were very pleased that the FDA agreed to a dual primary endpoint of blinded independent review committee or BIRC assess objective response rate or ORR and progression-free survival or PFS. TILVANCE-301 also includes several secondary endpoints such as overall survival and duration of response. In terms of trial design, we plan to randomize 670 patients who are naïve to therapy in the advanced setting, equally to either lifileucel in combination of pembrolizumab and the experimental arm of pembrolizumab monotherapy in the control arm. We are including an appropriate number of global sites, such as many large U.S. and European cancer centers and in numerous other countries, where we expect enrollment. In the control arm, patients will have the option to receive TIL monotherapy upon confirmed disease progression verified by the IRC. Additional information on trial design, outcome measures, and eligibility criteria are available on clinicaltrials.gov. Our confidence in the success of TILVANCE-301 is based on results from Cohort 1a in our IOV-COM-202 trial of lifileucel in combination with pembrolizumab in ICI-naïve advanced melanoma, in addition to prior data at the NCI for TIL monotherapy in anti-PD-1 naïve melanoma generated in the pre-ICI era. We look forward to advancing our frontline melanoma strategy through our 2023, ensuring site activation and patient randomization in TILVANCE-301. As Fred mentioned, TILVANCE-301 is expected to be well underway at the time of potential BLA approval for lifileucel in post anti-PD-1 advanced melanoma. We continue to execute on our non-small-cell lung cancer or NSCLC pipeline at Iovance, with six cohorts across three Iovance studies to investigate multiple treatment regimens in various populations at various stages of disease. We recently shared top-line initial data from Cohort 3A of the IOV-COM-202 trial, which we highlighted in the press release and investor conference call last month. Based on initial Cohort 3A positive results in patients with advanced NSCLC who are naïve to ICI treatment, particularly within the treatment-naive and post-chemotherapy success, we plan to meet with the FDA in 2023 to discuss data and the potential registration path for lifileucel in frontline advanced NSCLC patients. Enrollment in Cohort 3A is ongoing, and we plan to present detailed and updated results at a medical meeting this year. Our IOV-LUN-202 trial is investigating LN-145 monotherapy in patients who have received prior anti-PD1 and chemotherapy. In combination or sequentially and includes an option for pre-progression tumor harvest. We enrolled patients for 2022 and expect to continue enrollment this year. Moving to cervical cancer, enrollment is underway in our expanded Cohort 2 in the ongoing C-145-04 trials in patients who have progressed after chemotherapy and anti-PD-1 therapy. As a reminder, Cohort 2 is intended to be pivotal to support regulatory submissions following dialogue and feedback from the FDA. And we look forward to continuing Cohort 2 enrollment during the year. We are excited about our next-generation TIL therapy. We are developing several genetically modified TIL therapies that utilize the gene-editing TALEN technology licensed from selected to optimize TIL therapy by inactivating immune checkpoint proteins that inhibit anti-tumor response. IOV-4001 is our first genetically modified PD1 inactivated TIL therapy candidate. In the third quarter of last year, we treated the first patient with IOV-4001 in our first-in-human IOV-GM1-201 trial in patients with previously treated advanced melanoma or NSCLC. Additional programs using the TALEN technology are expected to enter clinical development in 2024, including genetically modified TIL therapy with multiple inactivated immune checkpoint targets. Earlier stage research and preclinical studies include additional approaches to increase TIL potency, including the selection of CD39/69 double negative TIL and enhancements, such as tethered cytokine. As part of our strategy to optimize the TIL treatment regimen, we also continue IND-enabling studies of our novel interleukin analog IOV-3001. I am available during the question-answer session. For now, I will hand the call over to Jean-Marc to discuss our fourth quarter and full-year 2022 financial results.

Thank you, Friedrich. My comments will summarize our planned acquisition of Proleukin as well as the high-level financial results from our fourth quarter and full year ended on December 31, 2022. More details can be found in this afternoon’s press release as well as in your SEC filings. Last month, we announced that we have entered into an agreement to acquire Proleukin from Clinigen. Terms of the agreement include an upfront payment of £167.7 million, the £49.7 million milestone payment upon first approval of lifileucel in advanced melanoma and double-digit Proleukin global sales royalties from Iovance to Clinigen. The transaction will be financed with existing cash and is expected to close after all conditions are met, including regulatory approvals and clearance and other customary closing conditions. As the late-stage oncology company approaching potential commercialization this year, we are also investing in launch preparations, return on manufacturing, and pipeline activities. As of December 31, 2022, we held $478.3 million in cash, cash equivalents, investments, and restricted cash compared to $602.1 million on December 31, 2021, taking into account proceeds raised in 2023 from our other market or ATM facility, our unaudited cash position is approximately $670 million as of February 24, 2023, which includes approximately $460 million in net proceeds raised through the ATM during the fourth quarter of '22 and into the first quarter of '23. The current and strengthened cash position is expected to fund our operating plan into the second half of 2024, including the Proleukin acquisition, manufacturing activities, launch readiness and execution, planned clinical trials, and pipeline advancements. Transitioning to the financial results for the fourth quarter and full year ended December 31, 2022, our net loss for the fourth quarter 2022 was $105.3 million or $0.64 per share compared to a net loss of $99.3 million or $0.63 per share for the fourth quarter of 2021. Net loss for the full year of 2022 was $395.9 million or $2.49 per share compared to a net loss of $342.3 million or $2.23 per share for the full year 2021. Research and development expenses were at $80.6 million for the fourth quarter 2022, an increase of $5 million compared to $75.6 million for the fourth quarter of 2021. Research and development expenses were $294.8 million for the full year 2022, an increase of $35.8 million compared to $259.0 million for the full year 2021. The increase in research and development expenses in the fourth quarter and full year 2022 over the prior year periods were primarily attributable to costs associated with the growth of the internal research and development team, including stock-based compensation expense as well as facility-related expenses and internal research programs. These increased expenses were partially offset by lower clinical and manufacturing costs driven by completion of enrollments in clinical costs of our clinical trials. General and administrative expenses were $26.5 million for the fourth quarter of 2022, an increase of $2.7 million compared to $23.8 million for the fourth quarter 2021. General and administrative expenses were $104.1 million for the full year 2022, an increase of $20.4 million compared to $83.7 million for the full year 2021. The increase in general and administrative expenses in the fourth quarter and full year 2022 compared to the prior year periods were primarily attributable to costs associated with the growth of the internal general and administrative and promotional teams, including stock-based compensation expense, the build-out of the new corporate headquarters, as well as pre-commercial activities. As of December 31, 2022, there were approximately 187.8 million common shares outstanding. I will now hand the call back to the operator to kick off the Q&A session.

Thank you. Our first question comes from the line of Peter Lawson from Barclays.

Great. Thanks so much for taking the questions. Fred, you said you are confident around the BLA submission by the end of Q1. What needs to be done there, what’s left?

Yes, Peter, we are really confident that we are going to get this done. We have essentially a lot of activities we talk about relating to the assay work, CMC work, validation work, and stuff like that, that we are completing. We have talked about it before. It’s relatively routine work, but it’s very important to the FDA, and that’s kind of what we are getting done here. So we can complete the rolling BLA submission.

Okay, okay. And then I know sometimes off, but just on the launch, lifileucel, are you expecting to see a bolus of patients on launch and kind of any way you can quantify that?

Sure. Given our experience in dialoguing with the KOLs at many of these sites in our – even our clinical trial experience, there is a high unmet need and this translates into a number of patients who are in need of therapy after checkpoint inhibitor. So we are expecting a bolus of patients at launch given that high unmet need.

And Peter, we do run an EAP program in order to stay in close contact with the site so that we are making sure that we have a good feel for what’s out there, adding care for patients, as the FDA wants you to do.

Thank you. Our next question comes from the line of Mark Breidenbach from Oppenheimer.

Hey, guys. Thanks for taking the question. Two quick ones for me. First, I am wondering if you can just comment on remaining barriers before you can begin recruitment into the TILVANCE-301 study? And then I am also wondering, aside from the Cohort 3A lung data, that Friedrich mentioned, are there plans for additional clinical data presentations in 2023? Thanks for taking the questions.

Friedrich, do you want to talk a little bit about the startup activities for 301, and you could probably talk about a little bit about the potential for lung data later this year too, if you want?

Sure. Happy to. Thanks for the question. So we have spoken about being in startup on TILVANCE-301. So that basically means submission of the protocol to sites, reviews at sites, like startup site initiation and then startup enrollment. There are no specific additional hurdles. That would be one hurdle that would apply to all sites; it’s now really activities at individual sites. And much of that work is basically going on in parallel and will continue as we are adding a meaningful number of sites both in the U.S. as well as ex-U.S., Europe and beyond Europe to the sites that will enroll to this trial. So really, no specific hurdle to site startup activities at individual sites. Does that make sense?

Sure. I guess I am trying to get a sense for when you would expect the first patient to be enrolled?

Yes, we haven’t guided to when exactly the first patient will be enrolled. What we have said though is that we expect enrollment to be well underway at the time of approval of the relapsed refractory indication. And I think that’s the main point here.

Yes, Mark, we would certainly advise everyone when we do randomize the first patient.

Got it. And then, with respect to other clinical presentations besides the Cohort 3A lung data?

Yes, I mean, I can cover that one. We have additional lung studies running right now, including the LUN-202 study, which could potentially read out this year. Plus, we already put out just a few weeks ago the 3A data, and we do want to get to a medical conference and draw on that data a little bit more deeply. So that will be I think a very important presentation for the company when that comes.

Okay, all the presentations will be in lung is what you are implying.

No, not necessarily. I thought you were just asking about lung.

No, no. I am trying to go for all other indications as well.

Yes, there are other – well, I can’t say for sure what we are going to do, but we’ve got a pretty thick pipeline and there could be other presentations, other indications for sure.

Thank you. Our next question comes from the line of Tyler Van Buren from Cowen.

Hi, guys. It’s Tara for Tyler. So I guess staying on the same topic of the lung data. So I know that when you just closed that few weeks ago or back in January, that it was too early to comment on response duration. But what do you kind of expect to see when the full results are presented? And then how are your discussions with the FDA going following that positive feedback that you received on study 202? Like, is there anything new to report there since January? Thanks.

Well, on the assuming the LUN-202 study?

Yes.

Yes, that’s one where we are engaging in discussions with the FDA. I don’t have any updates for you on that right now. Well, on 3A we are – like we said, when we released the data, the durability is something we are going to watch closely and it will certainly be part of our medical meeting presentation on that. I can’t really say much more about that ahead of time. That’s obviously an important thing to the content of the medical presentation. We do it, but we are very comfortable that what we are seeing should support a potential registrational trial like the one we described in January.

Thank you. Our next question comes from the line of Michael Yee from Jefferies.

Hi, everyone. Thank you for taking my question. This is on behalf of Michael. Since you have confirmed the BLA submission for Q1, I wanted to get more details on the progress made since the last update. Could you elaborate on the remaining factors that need to be addressed before submitting the BLA? Additionally, have there been any further communications with the FDA since the last update? Based on your discussions with them, can you share any insights on the possibility of an Advisory Committee meeting or a priority review? That would be very helpful. Thank you.

No, we haven’t had any additional interactions with them. We do expect to have priority review for this and we will know more about the AdCom at some point. We have spoken before about whether an AdCom is likely here; it’s possible we may not get an AdCom because it is familiar with T-cell therapies at this point. Raj has talked about that a few times on calls like this. With respect to the work and a little bit more color on the work, it’s, like I said earlier, it’s largely validation activities leading to some of the CMC stuff that we do, that’s part of our filings. I can tell you the bulk of the work for the BLA is done and submitted. So we are on the homestretch now and we are just completing some of these key tasks that take a lot of effort from the company. We have a lot of people here working very hard to get this done and really, it’s not the kind of thing where it’s extremely technical in nature; it will be very difficult to communicate with the Street on this, but it’s basically a lot of additional CMC validation activities, like we have spoken about before.

Okay, thank you.

Thank you. Our next question comes from the line of Ben Burnett from Stifel.

Great, thank you. I want to just ask about the launch preparations for lifileucel. Can you remind us just how many melanoma treatment centers in the U.S. you have already sort of onboarded, wherein you feel that you have sufficiently trained all the necessary stakeholders at a particular clinical site? Like how many clinical sites have you onboarded as per all of your clinical trial activities to date?

Thanks, Ben. This is Jim. The onboarding process is exactly that; it’s a process. We have engaged a number of key types across the country to ensure that we have sufficient geographic coverage as well as access. I won’t give you the specific numbers, but what we have stated in the past is, based upon our own assessment, looking at analogues like CAR-Ts, we know that there is a heavy concentration of care at these top centers. In the CAR-T market, about ten centers drive about 50% of all the treated patients and the top 40 about 80% of all the treated patients. So we are focused on getting the right sites up into our targeted and up ready for launch. We want to train them in the final phases of launch. If we train them too soon, there could be staff turnover, and there could be the recency. So what we are really doing is lining everyone up now? And as soon as we have the BLA acceptance, well BLA filing and acceptance, then we will start to really accelerate that final onboarding process.

Okay, understood. That makes sense. And then I want to ask just another question about the timing of data from the CRC program, in particular, the expanded CRC program in the post-chemo post-pembro setting. I guess, number one, do you have line of sight as to where we can get data? And then have you said how many additional patients needed to be enrolled there to kind of support BLA in that setting?

I think, Ben, you are not talking about colorectal; you are talking about non-small-cell lung right? You said CRC right. Yes, you meant CRC right. So I assume you meant non-small-cell lung; you got cut off there.

My apologies. I said the wrong indication.

Yes, we don’t have an ovarian indication at Iovance right now, although it’s certainly something we are very interested in and we have explored through IFPs.

Okay, my bad. I mistook that for a different program?

Too many earnings calls today.

Alright. I appreciate the help. Thanks, guys.

Thank you. Our next question comes from the line of Reni Benjamin from JMP Securities.

Hey, good afternoon, guys. Thanks for taking the questions. I guess just to start off maybe for Friedrich, the PD1 selected TIL studies, the PBL therapy, and the PD-1 inactivated TILs, can you give us a sense as to how those studies are progressing and kind of off Mark’s question, do you think this is something that we might see some initial data for at the end of this year? I guess that would be question number one. Question number two would be, the Proleukin revenues are supposed to be, I think, near-term or imminent right like once the deal is done? Can you just – I think you have talked about it in the past, but can you just remind us what sort of near-term revenues you expect from Proleukin this year?

Yes, why don’t I take the first one and then I’ll have Jean-Marc cover the revenues. We can’t give you guidance on revenues, Reni, but we can tell you historically, what revenues have been for that product and so you can figure out how to look when particularly upon the launch of lifileucel. For the PD1 selected and PD1 knockout, both of those programs are running, and we could be putting data on LMOs this year, at some point. PD1 knockout in particular is of high interest to us, that’s why it’s on the highlights of our portfolio because that particularly in lung and in melanoma should give us additional efficacy. So we are very excited about that. That’s one that when we have data, we will be putting it out pretty quickly. PD1 select is something we have been running for a while, and at some point, we will discuss that further. Jean-Marc, do you want to cover the revenue?

Yes, thank you, Fred, and thank you very much for the question. I mean, as Fred mentioned, we are not giving any kind of revenue guidance. First of all, we need to grow the deal first, and then we can talk and be more specific about the potential in the future. What we have publicly communicated is the revenue that was generated by Clinigen, which probably came in the past and we were mentioning 2021 was close to £30 million or $35 million, so that’s the only indication that we were giving in terms of past revenue.

Got it. Okay. And just one final one; this really just has to do with mainly the CEO search, is that still going, Fred? Are you trying to move your interim to something more permanent? And I will throw it out there, Christi Shaw has left Gilead, is someone close to that name joining anytime soon? That’s it for us.

Yes, I can’t say specifics like that, but the search is ongoing, and no, it won’t be me. So at some point, we will be able to talk more about that, and the Board is definitely interested in finding somebody who knows.

Thank you. Our next question comes from the line of Mara Goldstein from Mizuho Group.

Great. Thanks so much for taking the question. I just have a quick follow-up on Proleukin, and I respect you are not giving guidance, but I am just curious around your expectations about working capital and how the ATM figures into that as you onboard that product? And then secondarily, can you speak to the TILVANCE trial and how we should think about the primary endpoint in terms of the Delta improvement looking for given the number of patients in the trial? And secondarily, the presence of the crossover arm; just how do you account for pressure on the OS secondary endpoint there?

Yes, maybe Jean-Marc, you want to take the first part of that and then Friedrich get the second part?

Yes, sure. Yes, I am trying to think about the best way to answer your question. So I think our goal is to integrate Proleukin to the way that we will keep it as a profitable activity again, it will be separating away from lifileucel. So, we will have sale of Proleukin outside of our own usage. So currently I will say Proleukin is profitable, and we wanted to do the same in the future after integration. I am not too much concerned around working capital itself, because again, we are not talking about large amounts; we will not carry a lot of amounts of inventory, and everything should be pretty much managed correctly. So, no concern on that. ATM related, I mean, we have commented about the activity that we have just done. And I think what’s the most important there is to keep in mind we have enough cash, including the acquisition of Proleukin into the second half of 2024.

Yes, sure. Thanks for the question. So, I think that was like the two-part question, one of them was about how do we think about deltas that we are trying to achieve in the context of the study design and sample size. And the second question was about the crossover, so the first question, just I mean, I am just sitting in the office here is the design of the study is a randomized, comparative study. So, we are not shooting for specific deltas to an existing benchmark; we are shooting for a different or a hazard ratio between the two arms. What you usually do when you design a study like that, we do look at the best available information about what you might be expecting in your control arm and then you are powering in order to be able to get the difference or the hazard ratio is a little different from how we would have done this and are doing it in our single arm design. The information that we are pulling in for that is pretty straightforward; it’s available information on what you are seeing in a frontline population of patients treated with pembrolizumab monotherapy, and the information is available in the USPI for pembro or in publication. That’s probably as much as I can say here. The confidence here comes from our knowledge of what we are currently seeing in our COM-202 Cohort 1A, where the response rate is 66.7% with our last update and that would compare to something that’s in the low 30% for pembrolizumab monotherapy. So, that gives you an idea around the ORR. The crossover, so yes, obviously, the crossovers are something that you have to keep in mind as you are thinking about an overall survival endpoint, but that is exactly the reason why overall survival is not a primary endpoint yet. It’s fairly typical too in that situation, then go with a non-overall survival endpoint and we are particularly happy about having an agreement of being able to use ORR and PFS as dual endpoints in our discussion with the FDA. And that’s exactly the reason for it. The value of the crossover arm in this case is outweighing potential impact on the overall survival of the secondary endpoint.

Okay, thank you very much.

Thank you. Our next question comes from the line of Kelsey Goodwin from Guggenheim Partners.

Hey, guys. Thanks for taking my questions. I guess, first regarding manufacturing, I guess how do you think about kind of initial launch capacity and then the timing for step-ups if we are kind of thinking about it similarly to what we have been seeing with the autologous CAR-T therapies, to be just a bit more granular than kind of the Phase 1 Phase 2 that you lay out for the iCTC? And then secondly maybe just a quick one, are you able to provide any more color on your plans for potentially expanding into Europe for melanoma? Great. Thank you so much.

Yes, let me take the last one, and then Igor can give you some more color on the manufacturing. Yes, Europe is something we are very interested in. We haven’t publicly spoken much about Europe, but we are active there. Obviously, our trials have been run there and we continue to run them there. And TILVANCE-301 is going to have a significant European presence. We are engaged with the European regulators, and I think you’ll hear more from us in 2023 on that. But that is an important market, we think for melanoma as well as other markets around the world where we have a high incidence rate of melanoma. Igor, you want to answer the manufacturing question?

Happy to, Kelsey. Thanks for the question. So as I mentioned earlier, we have built the capacity, because the facility is built, can support more than 2,000 patients per year. And we are now hiring the manufacturing team to meet the demand that we anticipate at launch. We are not sharing the exact demand numbers, but as Jim mentioned, actually, in response to an earlier question, we expect maybe a bolus. So, we are taking that into consideration as we are planning the initial launch capacity. Beyond that, we can continue hiring staff as needed and then also build out the shelf space that we have within the existing iCTC facility that can bring us to over 5,000 patients per year. To increase the capacity step wise, there is a process that’s similar across TIL therapies, similar to CAR T that requires capacity general submissions to the agency, and we are planning those as well.

Okay, great. Thank you so much.

Of course.

Thank you. Our next question comes from the line of Asthika Goonewardene from Truist.

Hi, this is Karina for Asthika. Question – my question is for TILVANCE-301 study, how long will it take for you to finish recruitment? And given that the study is open-label, do you plan to report interim data, and if so, at what point? Thank you.

Friedrich, do you want to take that?

Yes. So the projection of accomplishing the analyses is hard, particularly when you are in the early phases of startup. I think we will better understand that once we start to make progress on enrollment and site activations. Also keep in mind that ultimately the endpoint, particularly the TSS endpoints are event-driven and a true and exact projection is never really possible because of that. So stay posted on that. The repeat the second question about the study please. Yes, you were saying that this is an open-label study; it’s actually not, it’s a blind study. So we are blinded to the treatment assignment as we would in any other study design, the assessments are done by a blinded independent radiology committee. So there is probably no update in between other than as the final decision is being made by the CMC.

Okay. And also, I have another question. You said that you did not expect to get REMS, is that probably the case?

Yes, that’s the – we don’t see any reason why we will get REMS; the total treatment regimen, Cy/Flu and IL-2 don’t have REMS today. So TILs don’t really carry any safety issues themselves. So we don’t see – we don’t have the issues that you see with some of the CAR-Ts that triggered the REMS in those cases.

Okay, thank you.

Thank you. Our next question comes from the line of Madhu Kumar from Goldman Sachs.

Hi. This is Madhu. Thanks for taking our question. Can you share your thoughts on the timing of the data from the cervical cancer cohort? Also, regarding the genetically edited TIL products, what are your expectations for efficacy or areas where you think you could improve?

Yes, we are working on genetically engineered TIL products that combine two approaches. Our goal is to achieve additive efficacy from the TIL response and the direct blockade of inhibitory mechanisms within the cell. As we incorporate additional immune checkpoint targets into our gene-editing process, we aim to enhance this effect further. This concept is somewhat analogous to the development of bispecific antibodies targeting PD-1 along with another factor. Currently, we have the PD-1 knockout trial in humans, and we will provide further updates later this year. Regarding cervical cancer, we have restarted enrollment in that pivotal study, but we do not have any updates to share at this moment. The post PD-1 cervical population is sufficiently large for reasonable enrollment, and we will have more information on that later this year. Thank you.

Thank you. At this time, I would now like to turn the conference back to Fred Vogt for closing remarks.

Thank you again for joining the Iovance Biotherapeutics fourth quarter and full year 2022 financial results conference call. We have had an exciting start to 2023 with the Proleukin agreement and new clinical data. We look forward to completing the BLA this quarter and delivering on our regulatory, commercial, manufacturing pipeline activities and milestones throughout the year. I am grateful for the patients, physicians, and regulators, as well as our employees and cross-functional teams who have worked in close collaboration to advance our mission to be the global leader in cell therapy. I’d also like to thank our shareholders and covering analysts for their support. Please feel free to reach out anytime to our Investor Relations team for any follow-up. Thank you.

This concludes today’s conference call. Thank you for participating. You may now disconnect.